Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02848781 · ClinicalTrials.gov registry record · NA

Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial

A NA study, sponsored by University of Arizona.

Completed
Registry status
NA
Development phase
180
Enrollment target

NCT02848781 is a NA study that has completed, run by University of Arizona. The registered enrollment target is 180 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02848781, a NA study, has completed, sponsored by University of Arizona.

COMPLETED
Registry status
NA
Development phase
180 participants
Enrollment target

Study Summary

The current standard of care for ventricular tachycardia (VT) includes the use of medicine called anti-arrhythmic drugs (AADs) and Implantable Cardioverter Defibrillator (ICD) therapy. These treatments are used to terminate the irregular heartbeats and bring the heart back to a normal rhythm. Catheter ablation is a procedure used to eliminate (damage) the heart cells causing the arrhythmia. Patients eligible for this may benefit from an ablation procedure in addition to an ICD to treat their VT condition or risk of developing VT. This study aims to show that treating VT with catheter ablation, if performed preemptively at the time of ICD implantation, will reduce subsequent recurrent VT, ICD shocks, and lead to improved survival.

Interventions

  • DEVICE Implantable Cardioverter Defibrillator (ICD)
  • PROCEDURE Catheter Ablation

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2015-11-30
Est. Completion 2021-03-29
Phase NA

Sponsor

University of Arizona

349 total trials

What the Registry Record Tells You About NCT02848781

The ClinicalTrials.gov registry entry for NCT02848781 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Implantable Cardioverter Defibrillator (ICD) is the first listed.

NCT02848781 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02848781 about?

NCT02848781 is a clinical study titled "Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial". The current standard of care for ventricular tachycardia (VT) includes the use of medicine called anti-arrhythmic drugs (AADs) and Implantable Cardioverter Defibrillator (ICD) therapy. These treatments are used to terminate the irregular heartbeats and bring the heart back to a normal rhythm. Cathet...

What is the current status of trial NCT02848781?

This trial is currently completed. It is a NA study. The enrollment target is 180 participants. The study started on 2015-11-30. Estimated completion is 2021-03-29.

What interventions are being tested in trial NCT02848781?

The interventions under investigation include: Implantable Cardioverter Defibrillator (ICD) (DEVICE), Catheter Ablation (PROCEDURE).

Who is sponsoring clinical trial NCT02848781?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.